A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

This study has been completed.
Sponsor:
Information provided by:
UCB Pharma
ClinicalTrials.gov Identifier:
NCT00105040
First received: March 3, 2005
Last updated: December 5, 2013
Last verified: February 2010

March 3, 2005
December 5, 2013
September 2004
March 2007   (final data collection date for primary outcome measure)
Characterize potential cognitive and neuropsychological effects of levetiracetam as adjunctive treatment in children 4-16 years old with refractory partial onset seizures compared to placebo attention/memory scale (Leiter-R) a
Potential cognitive and neuropsychological effects of levetiracetam as adjunctive treatment in children with refractory, partial onset seizures
Complete list of historical versions of study NCT00105040 on ClinicalTrials.gov Archive Site
Scores on memory/learning battery (WRAML-2), behavioral scale (CBCL), and quality of life scale (CHQ) after 12 weeks of double blind treatment
Not Provided
Not Provided
Not Provided
 
A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mg/kg/Day, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4 - 16 Years Old, Inclusive, With Refractory Partial Onset Seizures

A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Epilepsy, Partial
Drug: Levetiracetam
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
87
March 2007
March 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pediatric subjects (4 - 16 years old) diagnosed with refractory partial onset seizures for a minimum of six months prior to Visit 1 experiencing at least two partial onset seizures during the four weeks prior to Visit 1 will be enrolled.
  • Subjects should be on a stable regimen of one or a maximum of two other AEDs for at least 2 weeks prior to Visit 1.
  • Subject must have an Intelligence Quotient (IQ) as assessed during Visit 1 of at least 70.
  • Subject and parent/guardian should be fluent in English.

Exclusion Criteria:

  • Subject must not have had previous treatment with levetiracetam unless, in the opinion of the investigator, the subject's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of levetiracetam was confounded by concomitant medication.
  • Subject is receiving benzodiazepines on a routine or chronic basic and is unable to discontinue use four weeks prior to Visit 1.
  • Subject has seizures too close together to accurately count.
  • Subject has a current psychiatric disorder other than mild to moderate attention deficit, behavior, or learning disorders.
Both
4 Years to 16 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States,   South Africa,   Canada
 
NCT00105040
N01103
Not Provided
Not Provided
UCB Pharma
Not Provided
Study Director: UCB Clinical Trial Call Center UCB Pharma
UCB Pharma
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP